Super Vision

Super Vision is a high-tech R&D enterprise dedicated to solving difficult human eye diseases and improving the quality of life for patients with eye conditions. It has full independent intellectual property rights and R&D production capabilities. The company has completed multiple rounds of equity financing from well-known institutions such as Waterwood Ventures under Tsinghua University's Industrial Development Research Institute, Peking University Medical Industry Fund, Zhonghui Health Industry Fund, and Dongsheng Bozhan Technology Development Co., Ltd. The company's core product, the "Ocular Muscle Neurostimulator," is the world’s first high-end medical device of its kind. This product is used to treat congenital nystagmus, a global challenge often referred to as an "incurable condition" in ophthalmology. The project has received numerous honors, including the 2020 "Dongsheng Cup" Global Innovation and Entrepreneurship Competition Grand Prize and the First Prize in China’s Medical Device Innovation and Entrepreneurship Competition, gaining widespread social recognition. The company also has products in development for treating high myopia, strabismus, and glaucoma.Currently, Super Vision has invested nearly 20 million RMB to build a 1,000-square-meter GMP cleanroom facility in Changping Beikong Hongchuang Science Park (Chaoyue Road, Building A, No. 1) for the registration and production of its first product, the i-NYS Implantable Ocular Muscle Neurostimulator (a Class III active implantable medical device).